Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to improve glycemic control in adults with type 2 diabetes. It works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ertugliflozina and ertugliflozine. Its PubChem CID is 44814423.
Ertugliflozin
| CAS No | 1210344-57-2 |
|---|---|
| Molecular Formula | C22H25ClO7 |
| Molecular Weight | 436.9 g/mol |
| Synonyms | (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to improve glycemic control in adults with type 2 diabetes. It works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine.
The listed CAS number is 1210344-57-2.
The listed molecular formula is C22H25ClO7.
The listed molecular weight is 436.9 g/mol.
(1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol.
The source lists ertugliflozina and ertugliflozine.